---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-278466"
form_type: "8-K/A"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:26:44.856562+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics Q3 2025 net loss $20.1M; completed Phase 1b enrollment for ELVN-001 in CML

## Summary
- Completed enrollment of randomized Phase 1b cohorts of ENABLE trial of ELVN-001 in CML; on track for Phase 3 pivotal trial in 2026.
- Cash, equivalents and marketable securities of $477.6M at Sep 30, 2025, expected to fund operations into first half 2029.
- Net loss of $20.1M for Q3 2025 vs $23.2M in Q3 2024; R&D expenses $18.2M, G&A $6.9M.

## SEC filing metadata
- accession: 0001193125-25-278466
- form_type: 8-K/A
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312525278466/0001193125-25-278466-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312525278466/elvn-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-278466
- JSON: https://secwatch.observer/filing/0001193125-25-278466.json
- Plain text: https://secwatch.observer/filing/0001193125-25-278466.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.